Mirum Pharmaceuticals, Inc.
- Jurisdiction
United States - ISIN
US6047491013 (MIRM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€368.41M - Gross margin
79.0% - EBIT
-€49.00M - EBIT margin
-13.3% - Net income
-€50.27M - Net margin
-13.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
|
|
|
|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
|
|
|
|
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
|
|
|
|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
|
|
|
|
Earnings Calls
Latest earnings call: May 8, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |